Daniel Mueller

Has grant

Full Professor

University of Toronto

Canada

Research Interests

Explore related searches

Professors in Canada Professors in Medical Science Medical Science professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Daniel Mueller is a Full Professor at the University of Toronto, Canada. His research areas include pharmacogenomics, antidepressant response in late-life depression, and clinical guidelines for managing major depressive disorder. Recent articles focus on integrative genetic variations related to psychiatric treatments and advancements in therapeutic drug monitoring.

Recent Grants

Grant: Close

Semaglutide in comorbid obesity and schizophrenia-spectrum disorders for metformin non-responders: a double-blind randomized control trial

Open Date: 2020-01-01

Close Date: 2025-01-01

Grant: Close

Validation study using pharmacogenomics testing in adults with neurodevelopmental disorders and mental health concerns

Open Date: 2020-01-01

Close Date: 2022-01-01

Grant: Close

The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People with Major Depression

Open Date: 2020-01-01

Close Date: 2022-01-01

Grant: Close

Predicting antidepressant remission in late-life depression using polygenic risk scoring and machine learning models

Open Date: 2020-01-01

Close Date: 2025-01-01

Grant: Close

Pharmacogenetics of lethal methadone and opioid overdosing

Open Date: 2019-01-01

Close Date: 2021-01-01

Articles (20)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (18)

Lisa Brown, PhD

UNITED STATES

Daniel Mueller

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics

Pharmacogenomic insights in psychiatric care: uncovering novel actionability, allele-specific CYP2D6 copy number variation, and phenoconversion in 15,000 patients

CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression

Polygenic score analyses on antidepressant response in late-life depression, results from the IRL-GRey study

Modulation of neural oscillations in escitalopram treatment: a Canadian biomarker integration network in depression study

Integrative Genetic Variation, DNA Methylation, and Gene Expression Analysis of Escitalopram and Aripiprazole Treatment Outcomes in Depression: A CAN-BIND-1 Study

Assessing remission in major depressive disorder using a functional-structural data fusion pipeline: A CAN-BIND-1 study

Large Individual Differences in Functional Connectivity in the Context of Major Depression and Antidepressant Pharmacotherapy

Systematic review of mitochondrial genetic variation in attention-deficit/hyperactivity disorder

Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study

An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels

An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels (10.1055/a-1625-6388)

Clinical Impact of Functional CYP2C19 and CYP2D6 Gene Variants on Treatment with Antidepressants in Young People with Depression: A Danish Cohort Study

Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial

Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial (vol 12, 101, 2022)

Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders

Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment

Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study

Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review

Collaborators (18)

Lisa Brown, PhD

Charles F Reynolds III

Laura B. Ramsey

Lakshmi N Yatham

Gustavo Vazquez

Zachary Taylor

Paul Cumming

Jimmi Nielsen

Raymond W. Lam

Guillaume Pare

G. Camelia Adams

Zainab Samaan

Andrea Protzner

Rudolf Uher

Ariel Frajerman

Giada De Palma

Nisha Ravindran

James Kennedy

Make your next move.